Hardy AIM 🎯 Profile picture
Jul 16, 2020 31 tweets 17 min read Read on X

MaxCyte is a cell engineering platform, which uses non viral mRNA for drug development in a wide range of diseases including
-Auto Immune Diseases

11 Commercial Licencing deals with over
-$800m in Milestone Payments Image

MaxCyte is based on their patented novel drug development approach which is Flow Electroporation

Flow Electroporation is reprogramming of Human T-Cells

What this means is they have a machine that can modify any human/patients cells in order to target a specific problem Image

This as I hope you will understand offers enormous potential to address a wide range of therapeutic issues all under the platform which they own

Companies which use their technology to discover drugs...
-Sanofi Image

Some of the partners listed below exploring cell therapy are world leaders in the field.

Crispr partners also with CureVac (a mRNA company) which is backed by the BMGF, highlighting the area of work is becoming an increasing sought after therapeutic division ImageImage

Now what gets me excited is their approach to Cancer, they have recently set up CARMA subsidiary

CARMA is the use of CAR T-Cells in Solid Tumour Cancers, CAR T-Cells have never been proven to work in solid tumours but MXCT are showing early positive indications Image

MaxCyte have set up a US Boutique to manage the financing and listing on a main US Exchange which is anticipated in 2021
(Post Phase 1 Data announcement for their study of MCY-M11 In Ovarian Cancer)

1 Specialist Life Science US Investor has already invested


Phase 1 is an open label dose escalation study for the treatment of Ovarian Cancer

So far they have seen mild side effects with initial encouraging efficacy in preventing disease progression in cohorts 2 and 3 Image


This Phase 1 Trial is to assess the safety profile of the drug at different concentrations before conducting a prolonged dose study at an optimal concentration

Stable disease has been achieved for 6 months in Reoccurring Ovarian Cancer after lines of Chemo

Note this stable disease was achieved in Cohort 2, a low dose for a short duration (3 weeks) yielding stable control of the cancer

This has formed an encouraging early clinical base for both safety and potential efficacy with prolonged repeated cycles

CARMA Platform
-This platform extracts an individuals own immune cells (T Cells)
-Genetically Modifies them to specifically target +kill cancer tumours
-Whilst doing this it also programmes the bodies immune system to self manufacture the genetically modified immune cells Image

This is the quickest CAR T Cell development globally.

With the ability to manufacture these genetically modified personalised cancer therapy within 1 day compared to 2-6 weeks for similar CAR T-Cell therapies

MCY-M11 -Phase 1 Ovarian Cancer Read Out H2 2020


Ovarian Cancer is a highly unmet area within oncology with only a few approved drugs, the focus on trying to delay tumour progression is the initial primary objective meaning the scope for improvement is huge Image

Classic Case of an AIM listed Pharma- 🚨MASSIVELY UNDERVALUED🚨 to its less advanced peer listed on the NASDAQ

That will change shortly as MXCT intends to list on NASDAQ Q1 2021


MaxCyte announce the development of their EXCITING
-mRNA CAR-T Cell Therapy for Cancer
which will list on NASDAQ in Q1 2021 under their CARMA Subsidiary

The announcement entails the next stage of demonstrating efficacy as I will now go on to explain Image

What is TREMENDOUS about this?

With only 1 single 3 week cycle, stable disease was achieved for 6 months💥

With the addition of Cyclophosphamide
-an immune pre conditioner
it is likely less side effects will occur and with repeat lower dose cycles administered it is... ImageImageImage

Highly likely stronger efficacy will be achieved. Showing Tumour regression and minimal side effects

CAR T Therapy is a very hot sector in oncology development right now, with this completely Novel Approach, MaxCyte is primed for a re rate over the following 12 months📈💥

Mr Calvin on @MaxCyte_info 's mRNA therapy

"It's exciting to think that the work we do at MaxCyte to design products to meet the needs of our customers helps to bring us closer to 💥breakthrough therapies💥 for patients. Image

MaxCyte’s webinar on the ongoing relationship with CRISPR on finding a potential C U R E for Sickle Cell Disease

A disease which distorts Red Blood Cell Shape and ultimately leads to deficiencies, strokes and lung problems

🔥Ground breaking🔥 pre clinical and mouse models suggest

This therapy
🚨CURES 30 - 50%🚨
of gene malfunction resulting in potentially normal function of Red Blood Cells

No Significant Toxicity events ✅

First patients to be dosed H1 2021 📈 ImageImage

This article demonstrates how MaxCyte's technology can successfully Genetically Engineer Human Immune Cells to make them more powerful at recognising and killing Cancer Tumours💥

Something which Iovance and Fate Therapeutics are working on📈


This article demonstrating superior transfection efficiency using MaxCytes technology including superiority over the widely adopted CRISPR spCAS9 $CRSP


Important to note adoption of their innovative technology is gaining traction in one of the hottest sectors in the world right now (Cell and Gene Therapy)

As they report financial results are expected to be ahead of market expectations Image

MCY-M11 gets me extremely excited as the very first data which is being obtained is showing that with a single low dose it stops cancer progression for up to 6 months with most side effects being Mild (Grade 1/2)

This disease control is shown in virtually every patient ImageImage

MCY-M11 is only the first generation (Least complicated) CAR T therapy MaxCyte subsidiary CARMA have produced

Many more optimisations/additions will likely now take place over the following years, similar to the evolution of Fate Therapeutics pipeline Image

As these therapies are approved for medical use how will all these doses of each therapy be made?

By buying each and every machine/cassette from MaxCyte🔥

Not only will MaxCyte achieve revenues via this avenue they will also receive


💰💵💰💵 ImageImage

This is a platform technology that is growing “EXTRAORDINARILY” year on year

The adoption and sought after demand is likely to continue to increase YoY

Future revenue potential is mind blowing 🤯 Image

The Motley Fool isn’t no fool 📈


Another look at the partners which MaxCyte work with

$EDIT $5bn
$CRSP $12bn
KITE- Acquired by $GILD For $12bn
$SGMO $2.5bn
$ALLO $4bn Image

🔥BOLD words from the CEO of CRISPR Therapeutics $CRSP 🔥

Securing access to the

💥Leading “Cell and Gene Therapy” delivery platform 💥 Image

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Hardy AIM 🎯

Hardy AIM 🎯 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AimHardy

Jan 11, 2021

Life expectancy over a 300 year time span

1800 to 2100

(IMO I believe millennials who looks after themself now will now live beyond 150 years old due to health care advancements over the following decades🤷🏼‍♂️)

Call me crazy 🤪
1800 to 1890

From 43yrs to 50yrs (16% incr)
1890 to 1980

HUGE jump

From 50yrs to 76yrs old (52% incr)
Read 7 tweets
Jan 9, 2021

I think the fact that MRx0518 is showing massive near term promise in cancer, yet 4D continue to focus on Parkinson's Disease shows me how excited and effective they believe MRx0029 may be for Parkinson's
(Market expected to reach $8.3bn by 2026)

medgadget.com/2020/02/parkin… Image

After discussing MRx0029 in the text, the author from 4D heavily alludes to bringing in a partner... Image

BOLD Statement

'MRx0029 has shown promise as a potentially
disease-modifying therapy, by indicating a potentially neuro-regenerative effect' Image
Read 6 tweets
Jan 7, 2021

Totally agree $CDAK are around 18months further advanced in the development of Exosomes (delivery vehicle)

#RENE Mcap= £60m
$CDAK MCap= $591m

3 Companies evaluating RENE's platform

Currently snowed under with demand off other companies for Proof of Concept trials ImageImage

Are exosomes going to play a big role in future cell and gene delivery?


One of the brilliant things which Exosomes do is they have the ability to pass through the Blood Brain Barrier delivering signals and regulation into the Brain

This is extremely difficult to do and most drug delivery mechanisms fail to do this ImageImage
Read 19 tweets
Aug 26, 2020

Today 4D announce phenomenal trial results for the combination of @Merck's KEYTRUDA with MRx0518 in Lung and Kidney Cancer💥🚨

A staggering 42% achieved clinical benefit in a population that had exhausted all other methods of disease/cancer treatment

For a population which has been resistant to all other lines of therapies, this is hugely encouraging... if they can treat the most resistant...
...cancers in terminally ill patients, this bodes EXTREMELY well for earlier lines of therapy😬

Also, as the patient population has no other effective treatment this significantly increases the chances of early approval off the back of Phase 2 data
Potentially FDA...
Read 10 tweets
Jul 23, 2020

Why I believe @4dpharmaplc are on the cusp of a multi hundred million pound licencing deal for IBD and IBS?


Great Video 'Our Approach' highlighting @4dpharmaplc world leading innovative concept

Harnessing the bodies own Microbiome (Gut Bacteria) to solve genetic imbalances and malfunctions commonly referred to as diseases


Are you excited yet?

Read 96 tweets
Jul 23, 2020

Why I believe @4dpharmaplc are on the cusp of a multi hundred million pound licencing deal for IBD and IBS?

Phase 1 data for @4dpharmaplc Blautix's treatment of IBS highlights significant efficacy

-82% Improvement in a reduction of symptoms
-More diverse stable gut bacteria

4dpharmaplc.com/application/fi… ImageImage

Interim Safety Data for Blautix Phase 2 larger study shows excellent safety profile

-Comparable to placebo

We are awaiting efficacy data from the Phase 2 study anticipated this Quarter

4dpharmaplc.com/en/newsroom/pr… Image
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!